Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes
Expression of Trop-2 and ephrin B2 may demonstrate therapeutic possibilities for patients with SH/DD, who usually have limited treatment options, particularly in small cell carcinoma, in which few targets have been identified. Clinical trials to investigate the efficacy of these novel treatments are warranted.
Authors
- Shreyas Joshi (ORCID: https://orcid.org/0000-0002-0020-5298)
- Melad Dababneh (ORCID: https://orcid.org/0009-0008-9877-3891)
- Faisal Saeed (ORCID: https://orcid.org/0000-0003-1194-2792)
- Dylan J. Martini (ORCID: https://orcid.org/0000-0002-0843-1222)
- Lara R. Harik (ORCID: https://orcid.org/0000-0001-7091-4076)
- Samuel Bidot (ORCID: https://orcid.org/0000-0002-4696-2817)
- Vikram M. Narayan (ORCID: https://orcid.org/0000-0003-3731-4209)
- Vaunita Parihar
- Jacqueline T. Brown (ORCID: https://orcid.org/0000-0002-1885-0906)
- Katherine Case (ORCID: https://orcid.org/0000-0003-2496-2039)
- Bassel Nazha (ORCID: https://orcid.org/0000-0001-6385-1329)
- Mehmet Asim Bilen
Institutions
- Emory University (US)
- University of Alabama at Birmingham (US)
- Massachusetts General Hospital (US)
- University School (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1093/ajcp/aqae161
- Citations
- 4
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Institutes of Health
- National Cancer Institute